Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2021
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2021
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Practice

Salmeterol (Serevent) asthma trial halted early

Eric Wooltorton
CMAJ March 18, 2003 168 (6) 738;
Eric Wooltorton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Reason for posting: A large, placebo-controlled trial of Serevent (salmeterol), a long-acting β2-receptor agonist (LABA), was recently stopped early amid concerns that the drug may be associated with life-threatening asthma episodes and asthma-related deaths. Although details of the trial have not been published, a recent Dear Healthcare Professional letter posted on the US Food and Drug Administration's Web site describes some interim findings (www.fda.gov/medwatch/SAFETY/2003/serevent.htm).

The drug: Salmeterol is a long-acting (12 hours) agonist of β2-adrenoreceptors with a slow onset of action (10–20 minutes).1 It is indicated for use in patients with asthma and chronic obstructive pulmonary disease (COPD)1 and may also prevent high-altitude pulmonary edema.2 Salmeterol is marketed as Serevent, and is combined with fluticasone in the Advair Diskus.3

With hopes of resolving controversy about the safety of LABAs,4,5,6,7 the Salmeterol Multi-center Asthma Research Trial (SMART) was initiated in 1996. In addition to their usual asthma therapy, patients were given either salmeterol (42 μg twice daily) or a placebo for 28 weeks. The primary end point was the combined number of respiratory-related deaths and life-threatening events (requiring intubation and mechanical ventilation). Secondary end points included asthma-related events (including deaths). In a routine interim analysis of data for nearly 26 000 patients in late 2002, the salmeterol group showed a nonsignificant trend toward more asthma-related life-threatening events (including deaths) than did the placebo group.

Among the black patients (17% of the study population), there were significantly more primary and secondary outcomes in the salmeterol group than in the placebo group. No such difference was seen among the white patients (71% of the study population). No other ethnic subgroup data were analyzed owing to small numbers. The black patients had more frequent symptoms and worse peak expiratory flows at baseline and more intubations, emergency department visits and hospital admissions before study entry.

Fifty percent of white and 38% of black patients were using inhaled corticosteroids at baseline. Among the patients using inhaled corticosteroids, there was no significant difference between the salmeterol and placebo groups in primary or secondary outcomes. However, among patients not using inhaled corticosteroids, there were significantly more asthma-related deaths in the salmeterol group than in the placebo group.

What to do: Ethnicity may be a factor in asthma-related death8 and asthma care.9 Regardless, the SMART findings appear to reinforce Canadian asthma recommendations,10 which state that LABAs should play a role as “additional therapy” for those already managed with appropriate doses of inhaled corticosteroids. Salmeterol is not a substitute for inhaled asthma anti-inflammatory therapy and should not be initiated in patients with acutely deteriorating asthma. For patients already using the drug, acute symptoms should not be treated with salmeterol in place of short-acting β2-agonists. Patients with increasing requirements for short-acting β2-agonists may have deteriorating asthma and require prompt reassessment. Abrupt discontinuation of salmeterol is not advisable, as this can lead to serious asthma or COPD exacerbation.

Eric Wooltorton CMAJ

References

  1. 1.↵
    Serevent [product monograph]. In: Compendium of pharmaceuticals and specialties. Ottawa: Canadian Pharmacists Association; 2002. p. 1540-2.
  2. 2.↵
    Sartori C, Allemann Y, Duplain H, Lepori M, Egli M, Lipp E, et al. Salmeterol for the prevention of high-altitude pulmonary edema. N Engl J Med 2002;346:1631-6.
    OpenUrlCrossRefPubMed
  3. 3.↵
    Lemière C, Becker A, Boulet LP, Bowie D, Cartier A, Cockroft D, et al. Should combination therapy with inhaled corticosteroids and long-acting β2-agonists be prescribed as initial maintenance treatment for asthma? [editorial] CMAJ 2002;167(9):1008-9.
    OpenUrlFREE Full Text
  4. 4.↵
    Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993;306:1034-7.
  5. 5.↵
    Bunney R. Study too small to detect increase in deaths [letter]. BMJ 1993;306:1610.
    OpenUrl
  6. 6.↵
    Finkelstein FN. Risks of salmeterol? [letter] N Engl J Med 1994;331:1314.
    OpenUrlCrossRefPubMed
  7. 7.↵
    Mann RD, Kubota K, Pearce G, Wilton L. Salmeterol: a study by prescription-event monitoring in a UK cohort of 15 407 patients. J Clin Epidemiol 1996;49:247-50.
    OpenUrlCrossRefPubMed
  8. 8.↵
    Olopade CO, Rubinstein I. Salmeterol xinafoate vs albuterol in asthma: Was race a factor? JAMA 1994;272:1576.
    OpenUrlCrossRef
  9. 9.↵
    Akinbami LJ, LaFleur BJ, Scoendorf KC. Racial and income disparities in childhood asthma in the United States. Ambul Pediatr 2002;2:382-7.
    OpenUrlCrossRefPubMed
  10. 10.↵
    Boulet LP, Becker A, Bérubé D, Beveridge R, Ernst P, on behalf of the Canadian Asthma Consensus Group. Summary of recommendations from the Canadian Asthma Consensus Report, 1999. CMAJ 1999;161(11 Suppl):S1-12.
PreviousNext
Back to top

In this issue

CMAJ
Vol. 168, Issue 6
18 Mar 2003
  • Table of Contents
  • Index by author

Article tools

Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Salmeterol (Serevent) asthma trial halted early
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Salmeterol (Serevent) asthma trial halted early
Eric Wooltorton
CMAJ Mar 2003, 168 (6) 738;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Salmeterol (Serevent) asthma trial halted early
Eric Wooltorton
CMAJ Mar 2003, 168 (6) 738;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Beta-agonists modulate T-cell functions via direct actions on type 1 and type 2 cells
  • Long-acting {beta}2-agonists in asthma: safety concerns
  • Google Scholar

More in this TOC Section

Practice

  • Prostatic abscess
  • Relapsing fever in a traveller returning from Senegal
  • Orbital floor fracture
Show more Practice

Health and Drug Alerts

  • Nefazodone (Serzone) withdrawn because of hepatotoxicity
  • Safety updates: repaglinide (GlucoNorm) and bicalutamide (Casodex)
  • Paroxetine (Paxil, Seroxat): increased risk of suicide in pediatric patients
Show more Health and Drug Alerts

Similar Articles

Collections

  • Topics
    • Drugs: respiratory system
    • Drugs: adverse reactions
    • Asthma

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of the resources on this site in an accessible format, please contact us at cmajgroup@cmaj.ca.

Powered by HighWire